There has been no examination as to whether the prevalence of complementary and alternative medicine (CAM) use, as well as personal factors associated with CAM use and predictive of CAM use for women with female-specific cancers, is similar to those in other diagnostic groups. The purpose of this review is to compare CAM use and personal factors associated with and predictive of CAM use by women with female-specific cancers to samples of other diagnostic groups. If it is the case that CAM use is similar across various types of samples, then it may be unnecessary to continue to study detailed CAM use by those in separate diagnostic groups and instead focus energies on the examination of CAM therapies that may have risks for interaction with conventional therapies, such as biologically based therapies. The researcher concludes that we are now in an era in which we need to use our restricted time, human resources, and finances to examine biologically based CAM use that may carry high risks for interactions or toxicities for specific groups under examination, rather than examine global CAM use, unless the situation warrants such allinclusive study.
It is vital to know about the use of complementary and alternative medicine (CAM) by women with femalespecific cancers, particularly CAM therapies that have the potential to cause interactions with mainstream biomedical treatments. Female-specific cancers referred to in this article include cancer of the breast, cervix, ovary, and uterus. The National Center for Complementary and Alternative Medicine (NCCAM) defined CAM as "a group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine," 1 such as massage and acupuncture. Certain CAM modalities present a high likelihood of adverse interactions with mainstream biomedical treatments for women with female-specific cancers. They are also potentially toxic therapies that may be taken apart from conventional treatment, particularly if taken in the wrong dose (eg, too high a dose) or by the wrong route (eg, internal ingestion rather than external application). These include megavitamin therapy and nonvitamin, nonmineral, natural products that are herbal remedies. [2] [3] [4] [5] These are in the category designated by NCCAM as biologically based therapies. It is important to note that these CAM therapies may also have positive synergistic effects, such as the use of the herbal remedy milk thistle, which may decrease liver damage from chemotherapy. 6 There has been no examination as to whether prevalence of CAM use, personal factors associated with CAM use, and personal factors predictive of CAM use for women with female-specific cancers are similar to those in other diagnostic groups. Personal factors refer to biological factors (age, comorbidity, disability, pain, and type of cancer), sociocultural factors (marital status, education, income, race/ethnicity, insurance, and access to health care), and psychological factors (psychological distress, depression/anxiety, and perceived health status). 7 Associations describe a degree of relationship between variables, such as measures of chi-square or correlation coefficient. Predictors are variables that predict an outcome-in this case, CAM use or CAM use at risk for interactions or toxicities. Predictors are found in measures such as logistic regression, often used in the modeling process.
This review of the literature is part of the author's dissertation study, Complementary and Alternative Modalities Used by Women With Female-Specific Cancers. 7 The purpose of this review is to compare CAM use, personal factors associated with CAM use, and personal factors predictive of CAM use of women with female-specific cancers to samples of other diagnostic groups. If it is the case that CAM use, associations, and predictors are similar across various types of clinical or research samples, then it may be unnecessary to continue to study detailed use of all CAM used by those in separate diagnostic groups and instead focus energies on the examination of CAM types that pose risks for interaction with conventional therapies or other toxicity risks.
It is necessary to know the types of CAM used by women with female-specific cancers, specifically noting potentially problematic CAM, so that screening for CAM use with related teaching can be suggested across health care practice settings. Knowing personal factors of women associated with CAM use and those personal factors predictive of CAM use will promote safe CAM use. In fact, the National Cancer Institute recommended the following:
Cancer patients using or considering complementary or alternative therapy should discuss this with their doctor or nurse, as they would any therapeutic approach. Some complementary and alternative therapies may interfere with standard treatment or may be harmful when used with conventional treatment. It is also a good idea to become informed about the therapy, including whether the results of scientific studies support the claims that are made for it. 8 Sometimes women do not tell their health care practitioners about their use of CAM because they are afraid the practitioner will not approve of their use of CAM. 9, 10 This may lead to interactions from unsafe combinations of CAM and biomedical treatments, such as increased bleeding or decreased effectiveness of treatment. 5, 6, 11, 12 For instance, St John's wort, an herb commonly taken for depression, may cause increased clearance of antineoplastic drugs. 3 In breast cancer patients, it is possible for isoflavonoids from soy supplementation to enhance proliferative effects of estradiol in estrogen-dependent breast cancer cells, rather than inhibit such effects. 13 A comprehensive literature search was conducted using Medline, Cumulative Index to Nursing and Allied Health Literature, PsychInfo, and Allied and Complementary Medicine databases. Key terms included cancer, breast cancer, gynecologic cancer, ovarian cancer, uterine cancer, cervical cancer, complementary, alternative, integrative, and all of the terms relating to the personal factors under examination. Most of the studies were conducted with those who were receiving or had received conventional treatment. However, for other studies, it cannot be determined whether CAM use was in conjunction with mainstream treatment or instead of it because this information was not ascertained by researchers.
There are many studies regarding CAM use by women with breast cancer but few studies of CAM use by women with gynecologic cancers. A review of this literature is presented. Because this study focuses on CAM use by women in the United States, only those studies conducted on populations of women living in the United States are included in the review of literature for women with breast cancer. Due to the paucity of studies relating to CAM use by women with gynecological cancers, studies outside the United States were considered for inclusion in this review of literature.
There have been numerous studies of CAM use by those in other diagnostic groups. This literature is reviewed to compare and contrast it to CAM use by women with female-specific cancers. Two to 3 research articles for each diagnostic group were selected, unless only 1 could be located. Studies that were more recently published (since 2001) were given preference for inclusion. A total of 41 studies were examined.
Complementary and Alternative Medicine Use for Breast Cancer
There are a large number of studies regarding CAM use by women with breast cancer. Because this study focuses on CAM use by women in the United States, only those studies conducted on populations of women living in the United States are included in the review of literature. Nineteen studies that involved the use of CAM in women with breast cancer are reviewed in this section. Six of these, published in 1999 to 2001, [14] [15] [16] [17] [18] [19] are summarized in an article by Lengacher et al. 20 An additional review of 13 studies published from 2002 to 2006 is summarized in Table 1 . [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Upon review, certain patterns, associations, and predictors of CAM use emerge as commonalities for women with breast cancer. In all of the studies that examined demographic associations with CAM use, women were younger 14, 21 and had more education. 33 When demographic predictors of CAM use were studied, it was consistently found that women were younger, 7, 22, 26, 27 more educated, 17, 22, 26, 27, 29, 31, 33 and insured. 27 The only exception regarding age is a study by Navo et al, 31 in which older women were more likely to use CAM. However, the mean age of those who used CAM was 57.7 years, which is inconsistent with other CAM studies. Because the range of ages of women in the study was not provided, it is difficult to assess the findings. It is likely that there were not many women older than age 60, and thus "older" women is a relative term.
In studies from 1999 to 2001, CAM use by women with breast cancer ranged from 28% 16 to 84%, 18 with a midrange of 56% 15 to 65%. 14 But in studies from 2002 to 2006, the rate of use by these women increased, with only 1 study finding a low rate of 30% use 21 and most studies finding around 70% CAM use or more, 24 Ashinkaga et al, 2002 21 Bauer-Wu et al, 2006 22 DiGianni et al, 2003 23 148 173 236 67 Not given 77 72% reported using CAM that was helpful to recovery; 30% used at least 1 CAM therapy, 28% used none, and 22% used at least 2. Most common were herbal treatments (21%), meditation (21%), and traditional massage (20%). Significant positive correlations found between number of CAM therapies and education (r More than 90% used at least 1 type of CAM, whereas 68% used 2 or more. Frequency of CAM use did not change over 6 months. 75% used prayer or other spiritual practices on a regular basis, 33% have seen nontraditional healer in past 3 months, and 20% practiced yoga and/or meditation. Younger, more educated women were more likely to go to CAM practitioners, use herbal products, and spend more money on vitamins and herbal products (statistical values not given). Not given Most common sources of CAM information were magazines or books (69%), other survivors (64%), newspapers (54%), media (51%), family members or friends (50%), American Cancer Society (48%), medical journals (33%), Internet (20%), other cancer organizations (11%), and tabloids (9%). Most commonly used CAM therapies were exercise (75%), vitamins (71%), and prayer or spiritual practice (64%). Most common reason for using CAM was to prevent cancer recurrence (69%), followed by playing a more active role in recovery (67%). Benefits of CAM included reducing stress or helping people cope (82%), providing hope to people with cancer (77%), and reducing side effects (74%). Dangers were that CAM could provide false hope (15%), cause physical harm (8%), and provide no help (3%). High life satisfaction reported. Three most common CAM therapies used by women were prayer (58%), exercise (64%), and vitamins (63%). Sources of CAM information were usually other cancer survivors (55%) and family members or friends (53%). The most common reasons for CAM use were "to reduce risk of recurrence (96%), play a more active role in recovery (92%), boost immune system (89%), help manage stress (84%), and give them hope (82%)" (p 297). Satisfaction with treatment decision making was high. However, 61% wanted more assistance with knowing what questions to ask, 36% wanted more information about side effects of chemo, and 30% wanted to know about treatment options. 81% of women were very satisfied, and 14% were somewhat satisfied with their oncologist. At baseline, 39% used CAM, and 13% were planning to use it. At follow-up, 53% tried CAM, and 8% were planning to do so. Most women improved diets (54%), followed by use of vitamins (44%), herbs (44%), physical methods (18%), cognitive methods (11%), and spiritual methods (6%). Women who were more likely to use or plan to use CAM at baseline were younger (OR 77% used diet and nutritional supplements (the majority of these informed their physician), 78% used stress-reducing techniques, and 37% used traditional and ethnic medicines (most in these subscales did not inform their physician). Previous chemo and more than a high school education were associated with more frequent use of diet and nutritional supplements, as well as stress-reducing CAM. Having received chemo was associated with more frequent use of diet and nutritional supplements (ORs not given with up to 90% use by 2006. 22 Thus, it appears that CAM use for women with breast cancer has increased over time.
Commonly used CAM therapies included meditation, 15, 21, 22, 27, 33 imagery, 15, 19 support groups, 15, 16 psychotherapy/ cognitive methods, 15, 24 spiritual healing, 15, 19, 22, 24, 25, 27 prayer, 19, 22, 24 relaxation techniques, 16, 18, 28 herbal therapies, 16, 21, [27] [28] [29] 33 megavitamins, 16, 19, [25] [26] [27] [28] [29] [30] diet therapies, 8, 25, 28, 29 chiropractic treatment, 18 acupuncture, 18, 30 exercise, 19, 25 massage, 18, 21 and yoga. 22 Because CAM is often named as commonly used in this group of women, it is vital to ascertain whether the women are informing their providers of CAM use. However, studies indicate that not all women inform their health care provider of CAM use. 21, 31, 33 In 1 study, 21 researchers noted that more women communicated CAM use with their physicians than had been encountered in previous studies. They thought this might have been due to the women's high income levels and educational levels. Regarding those taking tamoxifen who did not report CAM use, they concluded, "It could be conjectured that women using tamoxifen might have utilized CAM therapies to deal with potential tamoxifen side effects and were unable or unwilling to relate these concerns to their physician." 21(p547) Lengacher et al 28 reported that women who did not share CAM use with their physicians decided that the therapies either were not harmful or would not be accepted by their physicians. They concluded, "If patients are not always forthcoming concerning CAM use, healthcare providers need to develop techniques to introduce discussion of CAM use and encourage this communication as part of the routine assessment process." 28(p1451) In a study by Shen et al, 33 patients using herbal medicine or other ingested products were more likely to inform physicians of their CAM use than those using other CAM therapies. The researchers surmised, "Many physicians do not lend credence to many of these CAM modalities, thus patients might be reluctant to discuss them." 33 Only 1 study compared use by women based on racial/ethnic groups. 17 Researchers discovered that African Americans most often used spiritual healing, Chinese used herbal remedies, Latinos used dietary therapies, and Caucasians used dietary methods and physical methods. Because most of the studies reviewed for this group of women include mainly or solely Caucasian women, information related to racial/ethnic use of CAM therapies is limited.
CAM is used by patients for a number of reasons, including relief of symptoms unresolved by mainstream biomedical care. Henderson and Donatelle 27(p56) stated, There were also high expectations that CAM use would improve quality of life-over 40% of CAM users indicated that improved quality of life was the single most important reason for CAM use. They also used CAM to feel more in control, strengthen the immune system, and reduce stress.
Users of CAM with breast cancer perceived themselves as having a higher risk of developing metastasis and dying from breast cancer than nonusers. 34 It may be that women are using CAM to restore their health, in hopes of preventing death from cancer. Hann et al 25 noted that women with breast cancer were aware that CAM use could provide false hope, cause physical harm, and provide no help. Yet a high life satisfaction from using CAM was still reported by the women.
Costs of CAM use for women with breast cancer ranged from $4 to almost $15 000, with a median cost of $70 per user/year. 32 If women are going to be spending money on CAM services, it is vital that their expenditures are worthwhile. Rakovitch et al 34(p147) concluded from their study of women with breast cancer, It is apparent from this and other studies that women are over-estimating the benefits of CAM while underestimating the potential adverse consequences of CAM therapies. . . . Alternative therapies based on flawed or absent scientific evidence of benefit can be harmful particularly if it leads to false hope for patients, delays in seeking potentially curative treatments at substantial costs, most of which is not reimbursed by private insurance. Alternative therapies may cause significant harm particularly if administered in excess of recommended dosages or if they interact with conventional treatments.
One of the predictors of CAM use for cancer survivors (breast and ovarian) was depression. 23 In other studies of breast cancer survivors, it may be that the use of psychological therapies relates to women's depression. However, such relationships have not been studied in these women.
Patterson et al 32 found that compared to patients with colorectal or prostate cancer, those with breast cancer were statistically significantly more likely to use any CAM therapy, see alternative providers, or take dietary supplements (P < .01). If this is indeed the case for all women with breast cancer, then these women may be more at risk for interactions with conventional treatments.
Gynecological Cancers
Gynecologic cancers are those specific to female reproductive organs, such as the cervix, fallopian tubes, ovaries, uterus, vagina, and vulva. 35 The types of gynecologic cancers that are examined in this article are cervical, ovarian, and uterine cancers. Most research studies relating to CAM use for these cancers group them together under the classification of gynecological cancers. Therefore, CAM use is considered under the umbrella of gynecological cancers.
Focus on Interaction Risks With CAM Therapies

Complementary and Alternative Medicine Use for Gynecological Cancers
There are a minimal number of studies regarding CAM use for gynecological cancers. Due to the paucity of studies relating to CAM use by women with gynecological cancers, studies outside the United States were considered for inclusion in this review of literature. One study is included that was conducted in Nova Scotia. 36 An additional study was conducted in 11 European countries. 37 Five research studies were conducted in the United States, 31,38-41 2 of which specifically concern ovarian cancer patients. 38, 41 One case report is also included. 12 All of these studies have been published only recently (between 2000 and 2006) . A summary of these studies is provided in Table 2 .
A study included in the review above regarding breast cancer patients 23 included a small percentage (5%) of ovarian cancer patients in the sample. However, 50% of the sample was breast cancer survivors (<1% other cancers and 44% no cancer history). Therefore, the study is presented in the section regarding breast cancer patients.
Before presenting the studies, it is important to note how little research has been conducted in the area of CAM use by women with gynecological cancers. Authors of an article regarding a literature review of botanical medicines with gynecological anticancer activity acknowledged,
We found a paucity of research on the use of botanical medicines for the prevention and treatment of gynecological cancers, and none of the eight agents reviewed have undergone clinical testing. While the actual frequency of CAM use among women diagnosed with gynecological cancers is not known, it is reasonable to assume that some of these women are using botanical agents purported, but not proven, to have anticancer effects. 42(p188) A scientific report was prepared by members of the Gynecology Cancer Disease Site Group in Ontario, Canada, which outlined the evidence available on CAM for women with gynecological cancers. The group members included gynecologists, oncologists, an oncology nurse, patient representatives, and methodologists. In the report, they emphasized, "The lack of sufficient high-quality evidence precludes definitive recommendations from being made." 11 The authors then offered opinions regarding use of vitamins A and C, physical activity, and relaxation therapy. They concluded, "The Gynecology Cancer Disease Site Group is unable to support or refute the use of any other complementary or alternative medicine therapy based on the limited evidence." 11 They added that it is imperative for health care practitioners and patients to discuss the use of CAM, so that practitioners can provide guidance with respect to potential benefits and risks. 11 Granai 43(p3) intended to write a manuscript regarding a review of CAM use by women with gynecological cancers. He quipped, "To do so would have been brief, indeed! No papers evaluating alternative medicine used specifically by women with gynecological cancers of the pelvis were found in peer review journals." Instead, he decided to start by writing about expectations such women might have regarding CAM. Granai concluded that physicians need to be open to dialogue with women about CAM use for gynecological cancers to meet the women's needs.
A case study regarding a patient with cervical cancer was presented by von Gruenigen and Hopkins. 12 This patient had a stage IIB squamous cell carcinoma of the cervix that involved the right parametria and upper vaginal fornix. Race and ethnicity of the patient were not provided. The patient's radiation therapy was delayed 9 days because of fever, chills, and diarrhea that began after ingesting multiple herbal and nutritional supplements.
The patient started 5 herbal supplements 10 days before her radiation therapy began. These included "supertonic," wheatgrass juice, Essiac, red clover, and Fen LB. Unknown to the patient, some of these remedies contained the same ingredients. For instance, Essiac contains red clover. Some research has been conducted on some of the remedies she was ingesting, but not enough to support such use. In fact, the patient spent $175 on the products at an alternative medicine seminar she and her husband attended. The seminar cost each of them $20. 12 The authors noted that they did not know if the herbs enhanced a radiation effect or if the symptoms that developed were solely due to the radiation therapy. However, they pointed out that the patient was taking high-fiber supplements and not following a prescribed low-residue diet during her radiotherapy, which likely contributed to the diarrhea. Therefore, it is not known how much of the symptoms were due to noncompliance with diet and how much were due to herbal usage. The symptoms the patient developed required 4 days of hospitalization to resolve. The researchers did not mention whether the patient developed these symptoms again later. 12 This case illustrated that CAM use may cause toxicity and delayed treatment. The researchers emphasized that CAM use needs to be asked about during history taking. They stated, "Our group has recently surveyed our practice population and have found that 66% of our gynecologic oncology patients are currently using alternative therapies and 59% were not disclosing this information to their physicians." 12 Few patterns, associations, and predictors of CAM use emerge as commonalities for women with gynecological cancers. This is due in part to the small number of studies that have been conducted with this population.
Variables associated with CAM use were younger age, 38 higher education, 31 and higher income, 39 although in 1 study, 37 there were no demographic differences between CAM users and nonusers. However, the sample size of 72 women was relatively small. Young age was associated with use of herbs for ovarian cancer. 38 In 1 study, it was discovered that gynecological oncology patients used CAM significantly more than other gynecology patients. 40 Only 1 study examined predictors of CAM use. 31 However, the sample consisted of equal numbers of women with breast and gynecological cancers. Predictors for each type of cancer were not delineated. The predictors identified were education, age, and disease status, with CAM used by those with higher education, older age, and those in remission. The mean age was 57.7 for CAM users and 55.0 for nonusers. The range of ages for the groups was 26 to 87 years for CAM users and 22 to 91 years for nonusers. Because only 1 study examined predictors, and those with gynecologic cancers were not delineated, no definitive conclusions can be derived.
Somewhat lower percentages of women with gynecologic cancers than those with breast cancer indicated they use CAM, ranging from the mid to high 40th percentiles 31, 39 to a maximum reported of 76%. 36 Commonly used therapies were dietary therapies, 36,41 prayer, 36, 40 exercise, 36, 40 megavitamins, 37, 40, 41 herbal therapies, 37, 38, 40 massage, 36 and mind-body therapies. 37, 41 Because commonly used CAM includes megavitamins and herbs, these women are at risk for interactions with mainstream treatments.
In 1 study, 38 only 5 of 41 women (12%) who reported using herbs consulted with an herbalist or other CAM health care practitioner for guidance about herb usage. One woman reported the side effect of hot flashes when taking black cohosh.
Researchers noted that CAM therapies need to be studied further, to establish effectiveness and safety or lack thereof. They concluded, As women and cancer patients have historically used these products more frequently than the population in general, it is imperative that the gynecological oncologist integrate this topic into the historical exam and be cognizant of the potential risks inherent in the unsupervised use of alternative therapies. 40(p208) Swisher et al 39 pointed out that even though some women did not receive all of the benefits they would have liked from CAM use, few were totally disappointed with CAM. They remarked on the lack of scientific evidence for the effectiveness or safety of CAM, particularly herbal remedies, which often have not been tested for quality control or contamination. They also asserted that some herbs, such as feverfew and ginger, have the potential to cause bleeding complications either alone or in combination with some mainstream medications.
Regarding cost, in 1 study, women spent a mean of $656 for CAM during the course of their treatment (range, $0-$7000), with 31.7% receiving insurance reimbursement. 40 In an additional study, it was noted that 18% of women in the sample spent more than $100 per month on CAM. 39 Researchers noted that diets such as the macrobiotic diet may lead to nutritional deficiencies if misapplied. All of this information points to the necessity of communication regarding CAM between the health care provider and patient. These researchers explained, An oncologist is likely to increase personal rapport and encourage patient trust by discussing this common practice. During this exchange, the oncologist will increase his own understanding of common practices, changing trends, and new fads regarding CAM usage in his or her own patient population. 39(p367) In 1 study, some women told their oncologists about their herb use because they wanted more information about the herbs (25%) and to be assured that the herbs would not interfere with chemotherapy (42%). Discussions between women and their physicians regarding herb use were most often (92%) initiated by the patients. 38 This is somewhat disturbing, as a health care provider should be asking the patients during assessment whether they use herbal therapies. The researchers concluded, Fifty-two percent of the women who used herbs reported trying to tell their oncologists about their herb use, however, the women felt disappointed when none of the oncologists were able to be more than supportive/neutral about their herb use. 38(p215) The women who did not tell their physicians about herb use (42%) cited the following reasons:
The oncologist did not have time to talk (11%), the patient had not seen the oncologist since starting the herbs (11%), the oncologist did not ask (11%), the patient did not think the oncologist would want to know (44%), and the patient knew that the oncologist would not be supportive. 38(p215) The lack of communication regarding herb use may lead to adverse effects, particularly in combination with chemotherapy for ovarian cancer. The researchers lamented, "By our current inability to provide inadequate scientific guidelines, are we leaving our patients and their billion-dollar demand vulnerable to exploitation by unproven health market forces?" 38(p216) The researchers summarized, Both patients and healthcare professionals need to be educated on the appropriate use of CAM during conventional treatment. However, before we can define the role of CAMs in conventional treatment of cancer, we need to learn more about the complex pharmacology of CAMs in appropriate preclinical studies and to design and initiate prospective clinical studies to establish the role of CAM therapy in modern medicine. 31(p676) McKay et al 36 noted that patients were only receiving about 15% of the information they would like about CAM from their oncologists. They concluded, Patients expressed an interest in receiving information on CAM medications and therapies, especially about safety and effectiveness. We hope that this study is a step toward providing the requested information and promoting discussions between patients and their caregivers about complementary and alternative treatment. 36(p568) 
Complementary and Alternative Medicine Use by Those in Other Diagnostic Groups
There have been numerous studies of CAM use by those in other diagnostic groups. To compare CAM use by women with female-specific cancers to those in other diagnostic groups, the literature regarding CAM use by others was examined. Two to 3 research articles for each diagnostic group were selected, unless only 1 could be located. A total of 41 articles were examined. Studies that were more recently published (since 2001) were given preference for inclusion, unless only older publications were available. Last, only research studies conducted in the United States were included, with 2 exceptions. First, the examination of gastrointestinal diseases included studies from Australia and the United Kingdom because there were no such studies of CAM use in this diagnostic group conducted in the United States. Second, 1 study from Italy was included in the examination of patients with headaches because no such studies in this category were conducted in the United States.
Emphasis in the review is placed on examination of variables of interest in the current study. In particular, variables associated with and predictors of CAM use and CAM use at risk for interactions are highlighted (see Table 3 ). The associations and predictors listed in Table  3 were statistically significant.
Complementary and Alternative Medicine Use by Men With Male-Specific Cancers
To ascertain similarities or differences in CAM use between those with female-specific cancers and those with male-specific cancers, several studies were examined in samples of men who used CAM for prostate cancer. Unfortunately, there were no studies published regarding CAM use by men with testicular cancer. For comparison purposes, statistics for studies related to the demographics of women with femalespecific cancers are related.
Factors associated with CAM use in men with prostate cancer include higher education; 24, 44 higher income; 44 other, unknown, or no insurance; 44 and more comorbid conditions. 44 The researchers do not identify the other categories of insurance that were examined. Also, those with higher biopsy scores, indicating worse tumor grade, were associated with CAM use. 44 It was found that those who used ingested CAM were younger. 44 Other factors associated with CAM use in men with prostate cancer include the finding that patients primarily treated with hormonal therapy were associated with CAM use, as opposed to those treated with either surgery or radiation. 45 Also, those who required additional therapy after initial treatment for prostate cancer were associated with CAM use, 45 as well as those who live in the Pacific West. 44 Predictors of CAM use in men with prostate cancer include higher education and higher income. 44, 45 Other predictors identified are more comorbidities, higher biopsy score, and those who live in the Pacific West. 44 Those who used ingested CAM have the same predictors, with the addition of younger age. 44 Specific types of CAM predictors are as follows: (a) men with higher stage cancer at diagnosis are more likely to use multivitamins; (b) Asians are more likely to use Asian traditional medicines and green tea than whites; (c) men with higher prostate-specific antigen (PSA) levels at diagnosis are more likely to use echinacea, green tea, and saw palmetto; and (d) nonwhite versus white men are more likely to report using massage or body work. 44 An additional predictor of CAM use in men with prostate cancer was need for additional therapy for their cancer after initial therapy. 45 This may relate to the severity of their disease or to comorbidities developed as a result of the disease. Also, the patients may have felt a greater need for hope and control in a situation when they needed additional treatment and thus turned to CAM use as a solution. -Patients primarily treated with hormonal therapy were more likely to use CAM than those treated with either surgery or radiation.
-Patients who required additional therapy after initial therapy were more likely to use CAM.
Any CAM use: -College education -Higher income -More comorbidities -Higher biopsy score -Live in the Pacific West Ingested CAM: -Similar to any CAM use, with the addition of younger men -Men with higher stage cancer at diagnosis more likely to use multivitamins -Asians more likely to use Asian traditional medicines and green tea than whites -Men with higher prostate-specific antigen levels at diagnosis more likely to use echinacea, green tea, and saw palmetto -Non-white vs white men more likely to report using massage or body work Not examined -Higher level of education -Higher income -Patients who required additional therapy after initial therapy -Higher percentage of patients would prefer to use a safe, effective herbal than a prescription medication (31% vs 11%).
-100% reported use of at least 1 CAM therapy.
-Biologically based therapies and alternative medical systems were used more often than mind-body and manipulative/body-based therapies.
-Preference for integration of CAM with conventional treatment.
-3 possibly dangerous uses of CAM were identified (echinacea can worsen asthma, topical menthol ingestion, water and coffee ingestion instead of medication for life-threatening situation).
-Prevalence of CAM use by those with CAD, CHF, vascular insufficiency, hypertension, and stroke, was similar.
-CAM use by those with CVD was similar to those without CVD.
-There were no demographic differences between CAM supplement users and nonusers.
- 71 Garrow and Egede, 2006 51 Lind et al, 2006 54 General CAM use: -Following a healthy eating plan was positively associated with use of vitamins/minerals, herbs, popular manufactured products, and CAM therapies.
-Foot inspection was positively associated with use of other home remedies. CAM use specific for diabetes management: -Following a healthy eating plan was positively associated with use of other home remedies, popular manufactured products, CAM therapies, and CAM practitioners.
-Self-monitoring blood glucose was positively associated with use of food home remedies and vitamins/minerals. There were no statistically significant differences in demographic variables (age, gender, and race) between CAM users and nonusers.
-Age, gender, or educational level did not affect CAM use.
-100% of respondents requested more education regarding CAM use in epilepsy.
-Nearly half of those using botanicals reported an increase in seizures.
-3 individuals reported brain hemorrhage that they blamed on ephedra-containing botanicals (ephedra has been linked to ischemic and hemorraghic strokes).
Groups were separated into consulters (those who had been to a general practitioner or CAM care practitioner at least once in past year for stomach/bowel problems) and nonconsulters (those who had not seen their general practitioner at all for stomach/bowel problems in past year). -Significantly more CAM users than nonusers would be interested in trying a CAM therapy; the difference was independent of perceived efficacy of CAM in the past.
Not reported -Those who used CAM as a substitute for conventional HIV therapy were less likely to take any antiretroviral medications than those who used CAM as a complement.
-Men, gay men, and those more educated, wealthier, and from the West were more likely to use CAM.
-Blacks were least likely to use CAM.
-Uninsured were most likely to use CAM with adverse effects or as substitution and not discuss it with provider.
-Those with the lowest CD4 cell counts reported the lowest use of CAM as a substitute for conventional therapy.
-Those who perceived providers' disapproval of CAM use were less likely to use CAM and less likely when they did so to disclose CAM use to provider.
-Those who distrusted provider reported higher CAM use and more CAM use as substitute for conventional HIV therapy. Not reported -Significant predictors of the number of CAM treatments used were higher lifetime number of conventional MD visits, those presenting with a comorbid psychiatric disorder, higher annual household income, and those who never used a pharmacological preventive therapy.
-Stage of disease (AIDS) was predictive of Asian CAM use, Latino CAM use, and plant-based CAM.
-Those with higher education used Asian CAM.
-Those who used Latino CAM were less likely to follow recommendations by their doctors, less likely to see their doctors when they were supposed to, and less likely to adhere to their medication regimen in the past 3 days.
-Men and patients with more education were more likely to use CAM.
-Blacks were less likely than whites to use CAM.
-CAM users were more likely to desire involvement in medical decision making and to have a negative attitude toward antiretrovirals.
-Those in younger age brackets and with higher levels of education were more likely to use CAM. Women and those with higher incomes were associated with CAM use. Those with Medicare/Medicaid were less likely to use CAM.
-Those seeing only CAM providers were younger than those seeing only conventional providers.
-The number of back pain visits for those seeing only CAM providers was higher than those seeing only conventional providers. However, mixers had the largest number of back pain visits compared to the other 2 groups.
-CAM-only users had claims for fewer comorbidities than the other groups.
-CAM use was associated with more education, higher income, non-Veterans Administration insurance, additional care outside the Veterans Administration, and the belief that lifestyle contributes to illness.
-The diagnosis of cancer versus chronic pain was not associated with differential CAM use.
-Strongest predictors of use of CAM provider were greater than minimal disability and use of a conventional provider.
-Sociodemographic: People with college or graduate degrees and 35 to 65 years old were more likely to report CAM use.
-Health related: CAM users were more likely to report at least 1 comorbidity (tended to be depression or ulcer/stomach problems); were diagnosed more recently; reported more symptoms, more pain, less dissatisfaction with female sexual functioning, and less energy; and
were more likely to report engaging in preventive health behaviors.
-Use and quality of care: CAM users reported greater use of outpatient services and tended to report better interpersonal care.
-Men were more likely to use chiropractic care but less likely to use naturopaths, acupuncturists, or massage therapists than women. -CAM was used more often than any other treatment except medications.
-CAM use associated with white race and younger age.
-CAM use was associated with younger age, higher income, college education or beyond, those who were married, younger age at onset of PD, and higher daily dosage of levodopa.
-CAM use was associated with younger age, higher education, more pelvic pain, and more painful intercourse.
-Use of CAM category of meditation/relaxation/prayer was associated with being Hispanic.
-Those who identified an accident as initiating their facial pain and those who reported a greater extent of pain interference with their social and work activities were more likely to use CAM.
-CAM use was associated with use of CAM medications, use of warm compresses, talking to others about pain, and use of other unspecified pain-reduction strategies. The use of each additional pain reduction strategy was associated with nearly a doubling of the odds of CAM use.
-Those who reported that they "did nothing" to reduce pain were less likely to use CAM.
-College-educated patients are 2.07 times more likely to use CAM than noncollege graduates, after controlling for age at onset and marital status.
-Married patients are 2.73 times more likely to use CAM than nonmarried patients for a given age at onset and education status.
-The OR for CAM use decreases by 0.95 for each year of increase in disease onset.
-CAM use was more likely in those reporting painful intercourse and those with a higher educational level. 
Education
The findings for men with cancer are similar to those of women with female-specific cancers. Generally, the CAM users are more educated. For instance, in a study of women with breast and gynecological cancers, 31 the researchers found that CAM use in breast cancer was related to educational status (χ 2 = 14.00, P = .003), with 64% of women reporting some college education. A similar trend was discovered in women with gynecologic cancers (χ 2 = 10.10, P = .02), with 61% of women reporting a postgraduate education. Researchers studying 551 women with breast cancer 27 found that higher education, specifically a college education, increased the likelihood of using CAM (odds ratio [OR] = 2.48, 95% confidence interval [CI] = 1.68-3.64, P = .000).
In a study of a cohort of 2582 prostate cancer patients, one of the predictors of any CAM use was higher education-specifically, college graduate or more (OR = 1.65, 95% CI = 0.88-1.69). In a study of 1099 men attending outpatient clinics for treatment of prostate cancer, higher levels of education increased the likelihood of CAM use (OR not given, P < .002). 45 Age Women with female-specific cancers who use CAM are noted in the literature to be younger. However, age has not been associated with general CAM use in men with prostate cancer. 44, 45 Younger age (less than 65 years) was associated with use of ingested CAM in a sample of 2582 men with prostate cancer. 44 However, what younger means is a relative term, and at times the particular age categories employed in studies are not given.
For example, in a study of 551 women with breast cancer who were posttreatment, 27 younger age was a predictor of CAM use (OR = 0.38, 95% CI = .022-0.62, P = .000). Unfortunately, the researchers did not specify where they separated younger from older women. However, they did note that the youngest participant was 31 years of age, and the oldest was 91 years, with a mean age of 64 years.
In a study comparing women with breast cancer to men with prostate cancer, 24 prostate cancer patients were significantly older (at least 60 years of age) than those with breast cancer (χ 2 = 5.4, P < .001). This is not surprising, as men are usually diagnosed with prostate cancer at later ages than women are diagnosed with female-specific cancers.
In women with early stage breast cancer receiving chemotherapy, 24 regression analysis controlling for psychological and medical variables showed that women who were younger were more likely to use CAM (OR = .90, 95% CI = 0.83-0.97, P < .01). Researchers examining women with breast cancer 27 found that younger age increased the likelihood of using CAM (OR = 0.38, CI = 0.33-0.62, P = .000). One of the predictors of CAM use for women with breast cancer was younger age (coefficient = -.037, SE = 1.336, P = .019). 21 
Income
Women with female-specific cancers who use CAM have higher incomes. In a study of 113 women with gynecologic cancer, 39 annual incomes greater than $30 000 per year were associated with CAM use (67.4% vs 32.6%, P = .01). In a study of a multiethnic sample of women with breast cancer, 17 among several groups, those who had incomes greater than $20 000/year were more likely to use CAM than those with lower incomes. These were blacks (62% vs 38%, P = .03), Latinos (61% vs 33%, P = .01), and whites (85% vs 59%, P = .01).
In contrast, in a study of women in Vermont, one of the predictors for number of CAM therapies used for women with breast cancer was lower family income (coefficient = -.0360, SE = 0.144, P = .014). 21 The researchers explained that this may have been due to age and income having counteracting effects, as age and income had a positive correlation with each other (r = 0.328, P < .001), and younger age was associated with number of CAM therapies used.
Prostate cancer patients using CAM also have higher incomes. In a study of a cohort of 2582 prostate cancer patients, one of the predictors of any CAM use was higher income-specifically, greater than $30 000 per year (OR = 1.56, 95% CI = 1.22-1.98). In a study of 1099 men attending outpatient clinics for treatment of prostate cancer, 45 higher income increased the likelihood of CAM use (OR not given, P < .002).
Comorbidities
Women who used CAM for breast cancer perceived themselves as having a higher risk of developing metastasis or dying from breast cancer than nonusers. 27 Similarly, men with more advanced prostate cancer, as well as more comorbidities, were associated with CAM use. 44 In a survey of 251 patients with breast cancer, 34 those who used CAM perceived their risk of cancer recurrence (mean score -.04 vs .42, P = .1) and death from cancer (mean score <-.53 vs .23, P = .0001) as being greater than nonusers.
In a study of prostate cancer patients, 44 those with more comorbid conditions (OR = 2.12, 95% CI = 1.57-2.88), as well as a higher cancer grading score on diagnosis (OR = 1.46, 95% CI = 1.01-2.10), were more likely to use CAM.
In summary, CAM use by women with femalespecific cancers is similar to those of men with male-specific cancers. Overall, those with male-specific cancers report using CAM less than women with breast cancer. 24 Because men are usually diagnosed with prostate cancer at later ages overall than women with female-specific cancers, "younger" men as opposed to "older" men with prostate cancer is a relative term.
Focus on Interaction Risks With CAM Therapies
Complementary and Alternative Medicine Use by Those With Other Cancers
In a study comparing CAM use by breast cancer patients to those with other cancers, it was found that CAM was used significantly more by those with breast cancer (84% vs 66%; P = .0003). Nutrition therapy, massage, and herbs were the top CAM therapies used in each group. These categories include CAM at high risk for interactions, so it is vital to assess for its usage across types of cancers, even though frequency of usage may not be as great in those who do not have breast cancer. 18 Researchers noted that breast cancer patients are more likely to be more consistent CAM users than those in the other cancers group (84% vs 66%, P = .003). 18 In the studies of those with other cancers compiled by the researcher for review, none of the researchers examined demographic differences between CAM users and nonusers 18,46,47 except for sex. 46 In a study of those with equal numbers of breast, colon, and prostate cancers, predictors of CAM use included the following: (a) high cancer-related symptom distress predicts increased dietary supplement use in men but decreased use in women, (b) dissatisfaction with a conventional provider predicts general CAM use in men and women, (c) desire for personal control predicts general CAM use in men and women, and (d) women are more likely to use alternative dietary supplements, alternative providers, focused mental therapies, and lifestyle changes than men. 46 
Types of Therapies Used
In a research study regarding supplement use with 75 083 men and women with a history of cancer, certain supplements were more likely to be taken at higher doses by those with certain cancers than those in cancer-free controls. 47 These were cranberry pills in those with bladder cancer (OR = 3.44; 95% CI = 1.86-6.35), soy in those with prostate cancer (OR = 1.99; 95% CI = 1.38-2.87), vitamin D in those with thyroid cancer (OR = 1.66; 95% CI = 1.21-2.28), zinc in those with ovarian cancer (OR = 2.19; 95% CI = 1.41-3.40), and melatonin in those with cervical cancer (OR = 1.86; 95% CI = 1.19-2.90).
When comparing CAM use by women with femalespecific cancers to those with other cancers, similar types of CAM therapies are used by the groups. In a study of 231 women with breast cancer, 15 29% used meditation and imagery, 32% used support groups, and 21% used spiritual healing. In a study of newly diagnosed breast cancer patients, CAM methods used were self-help groups (60%), relaxation techniques (59%), herbal therapies (43%), and megavitamins (39%). In a study by Morris et al, 18 breast cancer patients used nutrition (65%), massage (57%), herbs (49%), relaxation (41%), chiropractic treatment (43%), and acupuncture (31%).
Women with gynecological cancers used herbal medicine (34.5%), relaxation techniques (21.4%), and vitamins/ minerals (20.7%). 37 Newly diagnosed ovarian cancer patients reported using megavitamins/antioxidants (24%), herbal therapies (24%), movement/mind-body therapies (21.4%), and diet therapies (25%).
Psychological Factors
Psychosocial factors of desire for control and dissatisfaction with conventional providers found in those with female-specific cancers are found in other cancer patients.
For instance, in a study of 166 women with breast cancer, 24 women who were dissatisfied with their oncologist were more likely to use CAM at the conclusion of mainstream treatment (OR = 0.17, 95% CI = 0.03-0.87, P < .05). In a study of motives for CAM use in other cancer patients, 46 CAM use was positively associated with desire for personal control (OR = 1.73, 95% CI = 0.99-3.01). Dissatisfaction with a conventional provider increased dietary supplement use for men (OR = 2.33, 95% CI = 0.60-9.04), but decreased dietary supplement use for women (OR = 0.43, 95% CI = 0.12-1.48). 46 Because CAM use is categorized differently between studies, there is difficulty in making definitive comparisons. However, CAM use by women with female-specific cancers is similar to those with other cancers. Because demographic factors, with the exception of sex, were not examined in studies of those with other cancers, the researcher cannot compare CAM use based on factors such as age, race/ethnicity, and income.
Complementary and Alternative Medicine Use in the General Population
Demographic factors commonly associated with CAM use in the general population included being female, 48, 49 being younger 48 (particularly midlife 49 ), having a higher education, 48 and having a higher income if megavitamins and prayer were included as CAM therapies; otherwise, lower income was associated with CAM use. 48 Regarding associations of race with CAM use in the general population, in 1 study, 48 being black was associated with use of mind-body therapies, including prayer. In addition, being Asian was associated with CAM use, excluding prayer and megavitamins, and being white was associated with use of manipulative and body-based therapies.
Regarding ethnicity of CAM use in the general population, being non-Hispanic was associated with mindbody therapies, excluding prayer, whereas being Hispanic was associated with mind-body therapies, including prayer. 48 Grzywacz et al 49 divided CAM categories slightly differently, as well as race/ethnicity delineations. Being white, non-Hispanic was associated with use of alternative medical systems, biologically based therapies, and mind-body interventions. Being black, non-Hispanic was associated with use of manipulative and body-based therapies. Overall CAM use was associated with being non-Hispanic other. Other factors that were associated with CAM use in the general population were smoking and hospitalization. 48 This may reflect the presence of comorbidities, which can motivate people to seek additional assistance for symptom relief through CAM use.
Only Grzywacz et al 49 examined predictors of CAM use. Unfortunately, because of small sample size, those in the "non-Hispanic other" category were removed from analysis. The only common predictors for use of each of the 4 types of CAM were being female and having a higher income. Additional predictors for the use of alternative medical systems were being young, non-Hispanic whites and old, non-Hispanic blacks and having graduated from college. Additional predictors for the use of biologically based therapies were being non-Hispanic whites and old Hispanics. For manipulative and bodybased therapies, predictors were being young and old non-Hispanic whites. There were no additional predictors for use of mind-body interventions. 49 The difference in CAM use by age and ethnicity was explained as "reflecting differences in CAM availability and prevailing public health policies when adults began making their own health-related decisions." 49(p547) However, because a common predictor of CAM use for all CAM therapies was higher income, it may be that those with financial means access CAM, secondary in consideration to race, ethnicity, or age.
Because research that was conducted with women with female-specific cancers consisted of mainly white women, it is difficult to make comparisons between these women and studies of the general population, where usually more diverse samples were examined. Also, the use of various categories of CAM use employed by different researchers adds a complicating factor in trying to make comparisons.
However, in a study by Lee et al, 17 in which women with breast cancer were examined for CAM use based on racial/ethnic groups, it was discovered that African Americans most often used spiritual healing, which is similar to the finding of Barnes et al 48 that blacks used mind-body therapies, including prayer. Also, the finding of Barnes et al 48 that whites used manipulative and body-based therapies is similar to the finding by Lee et al 17 that Caucasians used physical methods.
In both female-specific cancers and the general population of CAM users, those who are younger, are insured, have higher incomes, and are more educated are more likely to use CAM. Those with lower incomes use CAM if multivitamins and prayer are excluded. 48 The main differences seem to be that use by race and ethnicity may vary depending on the category of CAM.
Complementary and Alternative Medicine Use by Those in Other Diagnostic Groups
Studies of female-specific cancers were also compared to those in other diagnostic groups. These groups include amyotrophic lateral sclerosis (ALS), Alzheimer's disease, arthritis, allergies, asthma, cardiovascular disease, diabetes, epilepsy, gastrointestinal disease, headache, HIV/AIDS, insomnia, kidney disease, mental health problems, multiple sclerosis (MS), pain, Parkinson's disease, and perimenopause.
Age
When age was examined, those who were younger were sometimes associated with CAM use. [50] [51] [52] [53] [54] [55] [56] [57] [58] Exceptions to this include samples of cardiovascular patients 59 and epilepsy patients, 60, 61 where age was not associated with CAM use. No studies showed older age to be associated with CAM use.
In contrast, a large study of the general population found a curvilinear relationship between CAM use and age. For instance, in a study of the general US population 48 using the 2002 National Health Interview Survey (NHIS) data, when prayer for health reasons was excluded from the definition of CAM use, the youngest (18-29 years, 17.7%) and oldest (85+ years, 6.4%) groups reported the least use of CAM. In contrast, 19.6% of those in 1 of the middle groups (50-59 years) used CAM. However, for all CAM therapies combined, those who were older were more likely to use CAM (85+ years, 70.3%). This was based on a sample of 31 044 adults in the United States.
Barnes et al 48 noted that those who were younger than age 65 years with public health insurance (65.1%) were more likely than those with private health insurance (61.4%) or no insurance (57.7%) to use CAM when the definition included megavitamins and prayer for health. Otherwise, adults with private insurance (39.4%) were more likely to use CAM than those with public insurance (31.1%) or no insurance (31.2%). In female-specific cancers, however, patients tend to be younger.
Regarding predictors for those in other diagnostic groups, CAM use was usually more likely in those of a younger age, 62, 63 particularly those in middle age. 54, 64 Notably, for women with inflammatory bowel disease (IBD), CAM use declined 1.2% with every 1-year increase in age. 65 This finding is similar to those with female-specific cancers.
Gender
Historically, women have been associated with CAM use. This was the case in only 3 studies, relating to arthritis, irritable bowel syndrome (IBS), and mental health, respectively. 52, 56, 66 In a study of those who were HIV infected, CAM use was associated with men and gay men. 67 In 3 studies, it was explicitly mentioned that there was no association between CAM use and gender. 59, 60, 61 It may be that the gender gap of CAM use is narrowing and that possibly for only certain problems is it more likely for a woman to use CAM more than a man.
In 4 studies, 53, [64] [65] [66] women were more likely to use CAM. In a study of those with back pain, women were more likely to use naturopathic care, acupuncturists, and massage therapists. However, men were more likely (OR = 1.11, 95% CI = 1.08-1.14) to use chiropractic care. 54 HIV-infected men were more likely to use CAM (OR = 1.31, 95% CI = 1.00-1.73) than women. 61 It may be that some CAM types may be used more often by men for certain conditions.
Income
Income level for CAM users was high in comparison to nonusers. 51, 58, 67, 68 For instance, in a study of veterans with pain, 68 CAM use was associated with an income greater than $50 000/year (91.2% vs 8.8%, P = .006). This was also the case in a study of those with Parkinson's disease, 58 where those with higher income levels were associated with CAM use (χ 2 not given, P = .038). Somewhat related to income level, those who were employed were associated with CAM use. 69 It is likely that those who have the financial resources to use CAM in addition to mainstream health care do so.
Having a higher income was usually predictive of CAM use. 63, 64, 70 In a study of 110 people with headaches, 70 those with a higher annual household income were more likely to use CAM (β = .16, t = 2.1, P < .001). Those with multiple sclerosis who had higher incomes of at least $50 000 per year were more likely to report CAM use (OR = 1.66; P < .05). 64 In contrast, using logistic regression, no sociodemographic variables were predictors of CAM use for a sample of those with anxiety and depression. 71 No studies indicated that low income predicted CAM use. This finding is the same for women with female-specific cancers.
Barnes et al 48 noted that those in the general population who use CAM have incomes more than $20 000/year compared to those with incomes less than $20 000/year (64.9% vs 61.6%) when multivitamins and prayer are excluded. However, it was found that those in the general population with lower incomes use CAM if multivitamins and prayer are included (37.0% vs 29.6%). 48 
Marital Status
The use of CAM was positively associated with marriage in 2 studies. 53, 58 This was the case in a study of those with IBD, 53 wherein those who were married were associated with CAM use (χ 2 not given, P = .05). Those with Parkinson's disease 58 who were married were associated with CAM use (84.6% vs 15.4%, P = .054). No studies reported unmarried individuals being positively associated with CAM use. There are no reports of marital status being associated with CAM use in women with female-specific cancers.
Being married was found to be predictive of CAM use in a sample of those with Parkinson's disease. 58 However, in a sample of those with anxiety and depression, 71 no sociodemographic variables were predictors of CAM use. No studies indicated that not being married was associated with CAM use. None of the studies reviewed using samples of women with female-specific cancers found marital status to be a predictor of CAM use. It seems that in populations in the United States, CAM use occurs independently of marital status.
Insurance
In the other diagnostic groups, having insurance was associated with CAM use, which is similar to those with female-specific cancers. To illustrate, in a study of veterans with pain, 68 having non-Veterans Administration (VA) insurance in addition to VA insurance was associated with CAM use (43% vs 28%, P = .003). It was found in a study of those with MS that those who had Medicare/Medicaid insurance were less likely to use CAM. 64 Those with cardiovascular disease who were uninsured were more likely to use herbal therapies. 63 It is possible that they used herbs instead of conventional care because of the inability to afford mainstream health care.
In a study of HIV-infected patients, 67 lack of insurance was associated with CAM use that could have adverse effects-to substitute CAM and not discuss CAM with a primary care provider (no insurance, 12.5%; Medicaid, 6.4%; Medicare, 9.9%; private insurance, 9.8%; P < .05). For those who must choose between CAM and mainstream care, they may be forced to choose the least expensive option, which is usually CAM care, particularly when it involves self-administered megavitamin/mineral supplements and herbal therapies. It was found in a study of those with MS that those who had Medicare/Medicaid insurance were less likely to use CAM (χ 2 = 4.51, P < .05). 64 Medicaid is insurance available to those who are indigent, so it is likely such individuals do not have sufficient funds to spend on CAM therapies. Because Medicare is used by those who are disabled or elderly, they also may not have the financial means to afford CAM. Because most insurance policies do not cover CAM care at this time, it is unlikely that insurance status will affect CAM use. If in the future, more insurance companies pay for CAM services, there may be a positive association found.
Ethnicity/Race
Several studies associated CAM use with non-Hispanic white ethnicity/race 52, 72 or white race. 55, 56, 73 Researchers of 2 studies in the other diagnostic groups noted that there was no association between CAM use and race. 59, 60 In a study of those with arthritis, 72 non-Hispanic whites were associated with the use of nutritional supplements, whereas Hispanics were associated with the use of oral herbs and items worn (ie, copper bracelets and magnets). Use of the CAM category of meditation/relaxation/prayer was associated with being Hispanic in a study of women with perimenopausal symptoms. 50 Differences in CAM use occur in relation to race and ethnicity, depending on the way in which CAM is categorized. For example, in a study of breast cancer patients, 17 African Americans most often used spiritual healing (36%), Chinese used herbal remedies (22%), Latinos used dietary therapy (30%), and Caucasians used dietary methods (35%) and physical methods (21%).
Grzywacz et al 49 combined 16 modalities into 4 of the 5 CAM groupings recognized by the NCCAM. Fewer non-Hispanic blacks used biologically based therapies (16.8%) and manipulative and body-based methods (4.6%) than non-Hispanic others (28.6%; 9.2%) and non-Hispanic whites (22.9%; 12.8%). Fewer Hispanics (13.2%) than non-Hispanic whites (19.1%), blacks (17.8%), and others (22.5%) reported using mind-body interventions. When examining any CAM use, with categories all together, CAM was used most by non-Hispanic others (44.0%), followed by non-Hispanic whites (39.0%), non-Hispanic blacks (29.7%), and Hispanics (29.3%). 49 Of interest is the measurement of association of acculturation to mainstream American culture with CAM use. In a study of those with arthritis, low-acculturated Hispanics were associated with the use of oral herbs and topical herbal rubs, whereas high-acculturated Hispanics were associated with movement therapies. 72 This difference shows that it may be necessary, therefore, to ascertain not only the ethnicity of respondents but also levels of acculturation.
There have not been any studies of those with femalespecific cancers that show that race/ethnicity increases the odds of CAM use. Several studies in other diagnostic groups associated CAM use with non-Hispanic white ethnicity/race or white race. This includes a study of those with mental health problems, 56 where there was an association between CAM use and being white in comparison to those who were Hispanic (acupuncture, 94.4%; massage, 99.2%; naturopathy, 98.3%). Similarly, in a study of those with facial pain from temporomandibular disorders (TMD), 55 those who were white were associated with CAM use compared to nonusers (χ 2 = 6.13, P = .01).
The use of CAM was more likely in those of the white race 67, 73 and races other than African American. 74 Asians with cardiovascular disease were more likely to use overall CAM and mind-body therapies. 63 In a study of those with arthritis, 72 being low-acculturated Hispanic was predictive of using oral herbs and items worn (ie, copper bracelets and magnets). However, in a study of those with anxiety and depression, sociodemographic factors, including race, were not predictive of CAM use. 71 Asians with cardiovascular disease were more likely to use overall CAM (OR = 2.1, 95% CI = 1.4-3.1) and mindbody therapies (OR = 2.5, CI = 1.7-3.9) 63 than whites, blacks, or Hispanics. However, in a study of those with anxiety and depression, sociodemographic factors, including race, were not predictive of CAM use. 71 Unfortunately, in many of the studies of CAM use in other diagnostic groups, race and ethnicity were not examined as variables. When they were, sample characteristics were not always reported to ascertain whether the sample was heterogeneous. Many researchers chose only to categorize participants as white, black, or other. Occasionally, researchers would designate ethnicity as Hispanic or non-Hispanic. In the study of cardiovascular patients by Yeh et al, 63 individuals were categorized by the following races: white, black, Asian, American Indian/Alaska Native, or other. Ethnicity was designated as Hispanic or non-Hispanic. Such thorough race/ethnicity delineations are not often seen in the CAM literature.
Education
A high educational level was usually associated with CAM use. [50] [51] [52] 58, [67] [68] [69] 73 However, in 1 study, educational level did not affect CAM use. 61 Higher educational level was consistently predictive of CAM use. 50, 58, [62] [63] [64] 67, [73] [74] [75] This educational level was usually identified as college or graduate-level education. This finding is similar to that of women with femalespecific cancers. For instance, in a study of 10 572 respondents to the 2002 NHIS with cardiovascular disease, 63 those with more education were more likely to use overall CAM (OR = 1.2, 95% CI = 1.1-1.5) and the category of mind-body therapies (OR = 1.2, 95% CI = 1.1-1.5).
The use of CAM was more likely for those with higher educational levels in the general population, regardless of whether prayer and multivitamins were excluded from the definition of CAM. 48 For instance, 48.8% of those with a master's, doctorate, or professional degree used CAM, excluding prayer and multivitamins, whereas only 20.8% of those with less than a high school education used CAM.
No studies were located where a lower educational level was predictive of CAM use. It may be that it is more than knowledge level of individuals with a higher education that predicates CAM use. Those with higher incomes are more able to afford additional education, so income may play a part in accessibility to CAM care. This finding is similar to that of women with female-specific cancers.
Comorbidities
For those with gastrointestinal diseases, 66 psychiatric comorbidity was not an independent predictor for CAM use. This is in opposition to findings of a sample of women with breast and ovarian cancer, 23 where women with depression were more likely to use CAM (OR = 4.6, 95% CI = 1.8-11.6, P = .000). In a sample of those with headache pain, 70 having a comorbid psychiatric disorder was a predictor of CAM use (β = .29, t = 3.88, P < .001). In a study of those with MS, 64 the comorbidity of depression was predictive of CAM use (OR = 1.48, P < .10). It is possible that those with gastrointestinal diseases choose CAM therapies for physical symptoms, rather than psychological ones.
Cardiovascular patients reporting worse health status were more likely to be CAM users (OR = 1.3, 95% CI = 1.1-1.6). 63 In patients with MS, CAM users were more likely to report more pain (OR = 1.01, P < .05) and more symptoms (OR = 1.08, P < .05). 64 Thus, it appears that those with lower health status and more comorbidities are seeking CAM care to alleviate some of their symptoms. This is similar to the finding in women with breast and gynecological cancers, in which those with more advanced disease status (recur/relapse as opposed to newly diagnosed) and those in remission were more likely to use CAM. 31 In a sample of those who were intravenous (IV) drug users, 73 having a lower health-related quality of life was predictive of CAM use. Similarly, in patients with MS, CAM users were more likely to report at least 1 comorbidity, more pain, and more symptoms. 64 In an additional study of MS patients, 74 one of the strongest predictors of the use of a CAM provider was greater than minimal disability. Thus, it appears those with lower quality of life, more comorbidities, and greater disability are seeking CAM care to alleviate some of their symptoms. This is similar to the finding in women with breast and gynecological cancers, in which those with more advanced disease status (recur/relapse as opposed to newly diagnosed) and those in remission were more likely to use CAM. 31 Women who are in remission have gone through treatments for cancer that may have left them with unwanted symptoms. The cancer diagnosis also has been a wakeup call for them that they need to be aware of their health and take care of themselves, so that cancer does not recur.
In a study of women experiencing facial pain from TMD, the use of each additional pain reduction strategy was associated with nearly a doubling of the odds of CAM use. 55 Similarly, women with perimenopausal symptoms reporting painful intercourse were more likely to use CAM. 50 In contrast, in a study in Australia with a sample of those with irritable bowel syndrome or dyspepsia, abdominal pain was a predictor of the use of conventional care. 66 Pain has not been identified in the literature as a predictor of CAM use for women with female-specific cancers.
Other Personal Factors
Other factors associated with CAM use in those in other diagnostic groups include anxiety and depression, 71 lower health-related quality of life, 73 more pain, 50 younger age at onset of Parkinson's disease, and higher dose of levodopa. 58 The use of CAM was associated with those who reported pain during intercourse in comparison to those who did not have pain (33.9% vs 25.0%, P < .05). 50 Other groups associated with CAM use include those who distrusted their conventional provider 67 ; those from the western United States 67 ; those with higher unadjusted annual expenditures, except for those with higher resource utilization bands (RUB) categories (groups people into 5 categories based on their expected level of resource utilization; lowest expected category is 1) 54 ; those who spend more money on prescription medications 57 ; those who make more primary care visits 51 ; and arthritis duration of 0 to 5 years. 52 From this information, one can speculate that those who have more money to spend on prescription medications and can afford to make more primary care visits may have available funds to spend on CAM therapies. Another explanation is that those who are sicker need to spend more on medications and make more visits to primary care providers, and thus they have greater intensity or frequency of illness that necessitates CAM use.
For patients with diabetes, 71 when examining CAM use specific for diabetes management, following a healthy eating pattern was associated with use of other home remedies, popular manufactured products, CAM therapies, and CAM practitioners. Other preventive health care strategies for managing diabetes and its complications were associated with CAM use. This indicates that those who use CAM may tend to participate in health promotion behaviors.
To summarize, CAM use by women with femalespecific cancers is similar to that by the general population. One exception is that those with female-specific cancers are younger, whereas at times, those who use CAM in the general population exhibit a curvilinear relationship between CAM use and age. Another exception is that race/ethnicity has not been associated with CAM use in those with female-specific cancers. However, race/ ethnicity has been associated with CAM use in other diagnostic groups. Depending on the diagnostic group and the way CAM is categorized, race/ethnicity associated with CAM use has been white, Hispanic, and Asian.
Conclusion
A total of 19 studies were reviewed regarding use of CAM by women with breast cancer. One difficulty in interpreting the findings is that there were a number of different tools used to measure CAM use and various categories of CAM used. It would be beneficial to develop a reliable and valid instrument to measure CAM use, to be used on a consistent basis.
Breast Cancer
Overall, a high percentage of women with breast cancer used CAM, and they did so for a variety of reasons. Most of these women were between the ages of 35 and 74, had higher incomes, had higher levels of education, and were Caucasian. A range of CAM therapies was used, and many women felt CAM was safe and helpful. In total, 27% 27 to 44% 26 used herbs, whereas 23% 27 to 71% 24 used vitamins. Women received information about CAM from a variety of sources. However, many women's primary health care providers were not aware of their CAM use. Cost of CAM ranged from $4 to $15 000 per year. There are no findings reported using recently collected data from a nationally representative sample.
Factors shown to predict CAM use, or to be associated with CAM use in women with breast cancer, included higher education, 20, 27, 34 private insurance, 27, 34 younger age, 15, 27, 34 psychological distress, 15 and being employed. 15, 34 Gynecological Cancers The use of CAM by women with gynecological cancers was described less frequently. Only 8 reports were found in peer-reviewed journals. Each of these studies was published only recently, between 2000 and 2006. As with breast cancer, there was no single instrument that was consistently used to measure CAM use. In general, many women with gynecological cancers used CAM for different reasons. Not as wide a range of CAM use is reported for these women as compared to those with breast cancer. This is due, at least in part, to the paucity of research conducted with this population.
These women received CAM information from several sources, with a greater percentage of them reporting their use to their primary health care provider as compared to women with breast cancer. This may be due to the more recent period of research with these women, as CAM use has become more acceptable. Most of these women were in their mid-50s, had a higher educational level, and were Caucasian. Costs were reported in only 3 studies and ranged from less than $10 per month to an average of $656 per month. In total, 24% 41 to 51% 38 used herbs, whereas 21% 37 to 24% 41 used vitamins. Factors shown to predict CAM use, or associated with CAM use in women with gynecologic cancers, include younger age 38 and higher income. 39 It was revealed that many women do not inform their health care providers about their CAM use. Most often, this is because the women are afraid providers will disapprove of CAM use. This may leave patients vulnerable to adverse interactions between certain CAM therapies and mainstream treatments. Therefore, communication between women using CAM and their providers needs to be enhanced, in order to prevent problems.
Costs of using CAM were discussed. Expenses for CAM may be minimal to extremely costly. Some of these costs may be covered by insurance, particularly in states where such coverage is mandated. Many times, however, CAM is not covered by insurance. Inability to pay for CAM services may prevent CAM usage by those who desire it. Because most CAM users reported in the United States were Caucasian, it is possible financial barriers prevented minorities from using CAM with greater frequency. Some women may use CAM instead of biomedical treatments when CAM is more affordable. Further research is needed in these areas to explain how costs affect CAM usage.
The use of CAM was shown to be associated with the presence of physical symptoms as well as psychological distress. Specifically, anxiety and depression were often associated with CAM use in patients with cancer.
Comparisons Between Patient Groups
Associations and predictors of CAM use for the general population, as well as those with male-specific cancers, other cancers, and those in other diagnostic groups, were explored. A total of 41 studies were examined. Comparisons were made between findings in these studies and those with samples of women with female-specific cancers. Overall, CAM use by the women was found to be similar to those with malespecific cancers, other cancers, the general population, and those in other diagnostic groups. However, some differences were found, depending mostly on how CAM use was measured and whether race/ethnicity was addressed.
According to population estimates, 80.9% of women in the United States with female-specific cancers used CAM. This is a higher percentage than was observed in earlier studies. In studies from 1999 to 2001, CAM use by women with breast cancer ranged from 28% 16 to 84%, 18 with a midrange of 56% 15 to 65%. 14 But in studies from 2002 to 2006, the rate of use by these women increased, with only 1 study finding a low rate of 30% use 21 and most studies finding around 70% CAM use or more, 20, 24, 27, 28 with up to 90% use by 2006. 22 Somewhat lower percentages of women with gynecologic cancers than those with breast cancer indicated they use CAM, ranging from the mid to high 40th percentiles 31, 39 to a maximum reported of 76%. 36 Thus, it appears that CAM use for women with female-specific cancers has increased over time.
Because there are many similarities in CAM use between those with female-specific cancers, those with male cancers, those with other cancers, and those in other diagnostic groups, it seems unnecessarily repetitive to continue to measure all CAM therapies used in every group of individuals. It seems a more cogent and fiscally responsible alternative to examine biologically based therapies that may have higher risks for drug interaction or other toxicities.
Because women with female-specific cancers may be using CAM therapies that may carry high risks, health care providers need to be certain to ask women whether they are using CAM that may cause adverse interactions. The health care provider will need to be educated as to which CAM therapies may cause negative interactions with mainstream treatments women may be using, so that appropriate education and suggestions for treatment choice decisions can be provided to the women.
For instance, for those receiving chemotherapy for cancer, it is vital to know whether they are receiving herbs or megavitamins that may interact negatively with mainstream treatments. However, it is not so vital to know whether they are receiving mind-body or energy therapies, such as Healing Touch or Reiki, which have no demonstrated adverse effects in those receiving chemotherapy and which this review has demonstrated to be among those widely used throughout several medical populations.
This author recommends using the 5 categories of CAM that are delineated by the NCCAM for researchers who collect and analyze CAM data. These 5 categories are alternative medical systems, mind-body interventions, biologically based therapies, manipulative and bodybased interventions, and energy therapies. 1 In the 2002 NHIS, energy therapies were combined in the category referred to as mind-body therapies because of the similarities between them. However, there are distinct differences, and when measuring CAM, it would be helpful to have separate categorization between the 2. In fact, an instrument to measure CAM based on the 5 NCCAM categories is currently under development and testing by Dr Saunjoo Yoon, assistant professor at the University of Florida (personal communication, February 23, 2007) . This researcher-administered survey instrument will include items more indicative of access to care, such as whether CAM is covered by insurance.
In conclusion, we are now in an era in which we need to use our restricted time, human resources, and finances to examine biologically based CAM use that may carry high risks for interactions or toxicities for specific diagnostic groups under examination, rather than examine global CAM use, unless the situation warrants such all-inclusive study. To do otherwise is a waste of limited assets.
